General Announcement::Outcome of the Board Meeting to consider repurchase of Foreign Currency Debt

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
13-Feb-2021 00:33:33
Status
New
Announcement Sub Title
Outcome of the Board Meeting to consider repurchase of Foreign Currency Debt
Announcement Reference
SG210213OTHRJBZD
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Description (Please provide a detailed description of the event in the box below)
We hereby inform you that, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, the Board of Directors of Glenmark Pharmaceuticals Limited ( Company ) at its meeting held on February 12, 2021, which commenced at 5:30 p.m. and concluded at 9:20 p.m., have considered and approved opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million (as on date outstanding U.S.$ 113.5 million) 2 per cent resettable onward starting equity linked securities due 28 June 2022 issued in 2016 ( FCC Bonds ) by the Company ( Bond Repurchase ), based on market opportunities and conditions from time to time.

Attachments

SGX_Outcome.pdf
Total size =100K